Covishield And Covaxin
- All
- News
- Videos
- Web Stories
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
Congress Leader Urges PM Modi To Allow Hybrid Classes As Children Remain Unvaccinated Against C0VID-19
In his letter to the prime minister, Congress leader Adhir Ranjan Chowdhury claimed that there is a lack of availability of Covaxin and Covishield, and most children below 18 years remain unprotected
-
Covishield, Covaxin Prices Cut To Rs 225 Day Before Booster Drive Begins
Serum Institute of India CEO Adar Poonawalla and Bharat Biotech cofounder Suchitra Ella today said that the decision was taken after discussions with the Centre.
-
Coronavirus Highlights: Covishield, Covaxin Prices Cut To Rs 225
The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.
-
Booster Dose Of Covid Vaccine Needed To Fight Against Omicron: Study
Neutralising antibody levels waned after six months in those who were fully vaccinated against the coronavirus with Covishield, Covaxin and a mix of both with regard to Omicron variant, a study done by the National Institute of Virology indicated.
-
Covishield, Covaxin To Be Available In Hospitals, Clinics In New Approval
Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.
-
Covid Vaccines Covishield, Covaxin Get Conditional Market Approval: Report
India's drug regulator has granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said today.
-
An Approval That Suggests Big Changes In Booster Policy Are Likely
Covaxin and Covishield could be more widely available with a new government approval that also suggests changes in rules for booster doses. Both vaccines have been cleared for "full use" by an expert panel of the central drug authority, a year after
-
Covishield, Covaxin Cleared For Market Approval By Expert Panel
An expert panel of India's central drug authority today recommended granting regular market approval to Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said
-
Facing Shortage Of Covid Vaccine: Maharashtra Health Minister
Maharashtra is facing a shortage of Covaxin and Covishield, said state health minister Rajesh Tope on Thursday.
-
Central Drug Regulator Approves Shelf Life Of COVID-19 Vaccines CoviShield, Covaxin, ZyCoV-D
The Central Drugs Standard Organisation (CDSO) has approved the shelf life of COVID-19 vaccines Covaxin to 12 months, Covishield to nine months, and ZyCoV-D to six months from the date of manufacture, the Lok Sabha was informed on Friday.
-
'Awaiting Lifting Of Curbs...': New Zealand's Nod To Covaxin, Covishield
New Zealand has included Covaxin and Covishield to its list of eight approved vaccines, Indian High Commissioner to the country, Mukhtesh Pardeshi, said today.
-
Covishield, Covaxin Recognised By 96 Countries, Says Health Minister
Union Health Minister Mansukh Mandaviya said on Tuesday that 96 countries have recognised Covaxin and Covishield and both these COVID-19 vaccines have received emergency use listing (EUL) from the World Health Organisation (WHO).
-
Australia Recognises Covaxin For Travel As It Eases Border Curbs
Earlier, the Therapeutic Goods Administration (TGA) had recommended that only the vaccines approved for use in Australia, and Covishield from India and Sinovac from China be recognised for the purposes of travel and other restrictions.
-
Zydus Cadila Agrees To Reduce Covid Vaccine Price To Rs 265 Per Dose: Report
Zydus Cadila's ZyCov-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
Congress Leader Urges PM Modi To Allow Hybrid Classes As Children Remain Unvaccinated Against C0VID-19
In his letter to the prime minister, Congress leader Adhir Ranjan Chowdhury claimed that there is a lack of availability of Covaxin and Covishield, and most children below 18 years remain unprotected
-
Covishield, Covaxin Prices Cut To Rs 225 Day Before Booster Drive Begins
Serum Institute of India CEO Adar Poonawalla and Bharat Biotech cofounder Suchitra Ella today said that the decision was taken after discussions with the Centre.
-
Coronavirus Highlights: Covishield, Covaxin Prices Cut To Rs 225
The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.
-
Booster Dose Of Covid Vaccine Needed To Fight Against Omicron: Study
Neutralising antibody levels waned after six months in those who were fully vaccinated against the coronavirus with Covishield, Covaxin and a mix of both with regard to Omicron variant, a study done by the National Institute of Virology indicated.
-
Covishield, Covaxin To Be Available In Hospitals, Clinics In New Approval
Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.
-
Covid Vaccines Covishield, Covaxin Get Conditional Market Approval: Report
India's drug regulator has granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said today.
-
An Approval That Suggests Big Changes In Booster Policy Are Likely
Covaxin and Covishield could be more widely available with a new government approval that also suggests changes in rules for booster doses. Both vaccines have been cleared for "full use" by an expert panel of the central drug authority, a year after
-
Covishield, Covaxin Cleared For Market Approval By Expert Panel
An expert panel of India's central drug authority today recommended granting regular market approval to Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said
-
Facing Shortage Of Covid Vaccine: Maharashtra Health Minister
Maharashtra is facing a shortage of Covaxin and Covishield, said state health minister Rajesh Tope on Thursday.
-
Central Drug Regulator Approves Shelf Life Of COVID-19 Vaccines CoviShield, Covaxin, ZyCoV-D
The Central Drugs Standard Organisation (CDSO) has approved the shelf life of COVID-19 vaccines Covaxin to 12 months, Covishield to nine months, and ZyCoV-D to six months from the date of manufacture, the Lok Sabha was informed on Friday.
-
'Awaiting Lifting Of Curbs...': New Zealand's Nod To Covaxin, Covishield
New Zealand has included Covaxin and Covishield to its list of eight approved vaccines, Indian High Commissioner to the country, Mukhtesh Pardeshi, said today.
-
Covishield, Covaxin Recognised By 96 Countries, Says Health Minister
Union Health Minister Mansukh Mandaviya said on Tuesday that 96 countries have recognised Covaxin and Covishield and both these COVID-19 vaccines have received emergency use listing (EUL) from the World Health Organisation (WHO).
-
Australia Recognises Covaxin For Travel As It Eases Border Curbs
Earlier, the Therapeutic Goods Administration (TGA) had recommended that only the vaccines approved for use in Australia, and Covishield from India and Sinovac from China be recognised for the purposes of travel and other restrictions.
-
Zydus Cadila Agrees To Reduce Covid Vaccine Price To Rs 265 Per Dose: Report
Zydus Cadila's ZyCov-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above
